Last checked at 29 Apr 2013 07:00
29 April 2013
Tissue Regenix plc ("TRX" or "the Company")
Change of Nominated Adviser and Broker
Tissue Regenix plc (AIM : TRX) announces the appointment of Jefferies International Limited as Nominated Adviser and Broker to the Company with immediate effect.
-ENDS-
Contacts:
Tissue Regenix plc
+44 19 0443 5176
Antony Odell
Ian Jefferson
Newgate Communications
+44 20 7680 6550
Alistair Kellie /Andrew Adie
Jefferies International
+44 20 7029 8000
Simon Hardy /Henry Elphick
About Tissue Regenix plc
TRX is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.
www.tissueregenix.com